Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AAM Urges Action On Product Hopping And Patent Thickets

Executive Summary

The AAM’s senior vice-president, Jeffrey Francer, has offered suggestions to US lawmakers on how to curb anti-competitive tactics used by originators.

You may also be interested in...



Sandoz Sees Revolution In US Biosimilars Market

Five years on from the first US biosimilar approval, the country’s biosimilars market is starting to fulfil its potential, in part driven by a recent oncology “revolution” according to Sandoz’ Sheila Frame.

Biosimilars Basics Explained To US Patients

Patient-oriented educational materials on biosimilars published by the US Food and Drug Administration have been welcomed by the local off-patent industry.

Biosimilar Patent Thicketing Has Cost US $7.6bn

A recent study by the AAM’s Biosimilars Council has found that delayed access to biosimilars has cost the US healthcare system $7.6bn since 2015; meanwhile, Medicare has foregone more than $1.2bn in savings from biosimilars since 2015.

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB149202

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel